Blog - QualityStocks

FridayApr 17, 2026 12:10 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease. SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug…

FridayApr 17, 2026 11:30 am

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Gains Relevance as Inflation, Conflict and Central-Bank Demand Reshape Gold

Disseminated on behalf of  Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising. Central bank gold buying has been unfolding against an international scenario that continues to favor safe-haven assets. Lahontan is working to build value through continued drilling, metallurgical work and project advancement. The company is showing a steady stream of updates this year, including drilling and key financing. Gold’s appeal rarely rests on a single catalyst, and the current environment is no exception. Rising geopolitical tension, stubborn inflation risk, elevated sovereign debt and continued official-sector buying are all feeding the case for a renewed gold cycle,…

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

FridayApr 17, 2026 9:10 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Closes $10 Million Public Offering to Advance Cardiac Technology Commercialization

HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes To view the full press release, visit https://ibn.fm/9iNYY About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the…

ThursdayApr 16, 2026 12:05 pm

QualityStocksNewsBreaks – Roth Capital Partners Appoints Seth Appel Head of ATM and Equity Alternatives Banking

Roth Capital Partners announced the appointment of Seth Appel as head of ATM and equity alternatives banking, bringing more than 30 years of capital markets experience to expand the firm’s equity capital markets capabilities and support growth companies in raising capital. In connection with the appointment, Appel will also serve as co-chief investment officer of the RoHo Capital Opportunities Fund, a joint venture with Horizon Technology Finance Corporation (NASDAQ: HRZN), focused on providing debt financing solutions to small- and micro-cap public companies. To view the full press release, visit https://ibn.fm/Mxqo7 About ROTH ROTH is a relationship-driven investment bank focused on…

ThursdayApr 16, 2026 11:15 am

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Nears Drill Program Start as Part of Multi-Pronged Gold Revenue Strategy

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising. Canadian near-term precious metal producer ESGold is advancing toward the May start of a drill program expected to further define priority targets on its 20,618-hectare Montauban Gold-Silver Project in Quebec The company is simultaneously working to construct a fully permitted mill on site and expand the scope of its exploration ESGold is employing a low CapEx strategy that includes funding from a private placement initiative and an agreement with Ocean Partners UK Ltd. that provides a credit facility and a dedicated buyer of gold and silver…

ThursdayApr 16, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting. In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma. Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides both an encouraging…

ThursdayApr 16, 2026 10:30 am

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Launches Quantum-Ready HPC GPU Network in New York and Philadelphia

Datavault AI (NASDAQ: DVLT) a provider of data monetization, credentialing, digital engagement and real-world asset tokenization technologies, announced that the first sites of its quantum-ready high-performance computing GPU network are now live in New York and Philadelphia, with full commercial availability of its planned 48,000-GPU fleet expected in Q3 2026. The network, designed to operate outside the hyperscaler supply chain, will scale across 1,000 micro-edge sites in more than 100 U.S. cities and support low-latency AI inference, data tokenization and monetization through the company’s IDE(R), DataValue(R) and DataScore(R) platforms, positioning it as an alternative source of secure enterprise AI compute capacity amid ongoing GPU supply constraints. To view…

ThursdayApr 16, 2026 9:48 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports FY 2025 Net Income of $249 Million

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on orphan oncology and advanced drug platforms, reported financial results for the fiscal year ended Dec. 31, 2025, with net income of approximately $249.0 million compared to a net loss of $4.8 million in FY 2024, primarily driven by a non-cash gain of approximately $365.4 million from the increased valuation of its GMP Biotechnology joint venture, partially offset by a deferred tax provision of $111.6 million. To view the full press release, visit https://ibn.fm/imTdU About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State…

ThursdayApr 16, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation

Oncotelic Therapeutics has recently entered a strategic partnership with TechForce Robotics to commercialize a PDAOAI-enhanced, GMP-compliant robotics platform The collaboration integrates AI-driven compliance systems with advanced robotics for pharmaceutical manufacturing automation This pivot underscores a broader strategy: extending Oncotelic’s AI capabilities beyond therapeutics into scalable, high-value industrial applications Oncotelic Therapeutics (OTCQB: OTLC) is signaling a significant strategic evolution, moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation,…

Site Search

Company Search